Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene Therapeutics filed a Form 8-K reporting the results of its 2020 Annual Meeting of Stockholders held on June 5, 2020. The record date was April 21, 2020, when 125,310,920 shares of common stock were outstanding and entitled to vote.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial performance metrics.
Material Changes Versus the Prior Comparable Period
No comparative financial or operating information is presented. The principal reported developments were stockholder voting outcomes and the election of directors.
Voting Results, Outlook, and Other Matters
- Election of directors: Deborah Messemer, Todd Sisitsky, and Owen Witte, M.D. were elected as Class II directors, each to serve until the 2023 Annual Meeting and until a successor is elected and qualified.
- Say-on-pay frequency: Stockholders approved, on an advisory basis, holding future advisory votes on executive compensation every one year. Votes were 95,406,161 for one year, 16,363 for two years, 12,148 for three years, and 1,353,502 abstentions.
- Independent auditor: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. Votes were 103,463,830 for, 41,328 against, and 4,751 abstentions.
- The filing contains no management guidance, financial outlook, material contingencies, or unusual financial items.
Key Facts for Investors to Verify
- Confirm the election and continuing service terms of the three Class II directors.
- Verify that the advisory executive-compensation vote will be conducted annually.
- Verify Ernst & Young LLP’s ratification for the fiscal year ending December 31, 2020.
- Note that the filing is limited to annual-meeting matters and does not update the company’s financial condition or clinical and business outlook.